Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. reports developments as a clinical-stage biopharmaceutical company focused on therapies for fibro-inflammatory diseases. Company news centers on Thykamine™, including preclinical data in MASH and pulmonary fibrosis models, anti-inflammatory and anti-fibrotic research, intellectual-property filings, manufacturing controls and its radiodermatitis prevention program.
Recurring updates also cover Devonian's cosmeceutical activities, its Quebec extraction facility and Altius Healthcare Group LP, a commercialization subsidiary that sells licensed prescription pharmaceutical products in Canada. Corporate news includes financial results, board and management changes, shareholder meeting outcomes, stock-option grants and capital-structure actions such as its common-share consolidation.
Devonian Health Group (OTCQB: DVHGF) reported the results of its annual general and special meeting held March 27, 2026.
Shareholders elected eight directors, appointed MNP LLP as auditor for the fiscal year ending July 31, 2026, and approved an amendment to increase the stock option pool to 20% of issued shares (post‑consolidation), subject to TSXV final approval.
Devonian Health Group (OTCQB: DVHGF) reported a Q2 2026 net loss of $2.2M ($0.81/share) and a six-month loss of $3.8M ($1.37/share). Cash fell to $1.3M at January 31, 2026 from $7.0M on July 31, 2025. The company effected a 60-for-1 reverse share split on January 22, 2026 and remains debt-free.
Devonian is refocusing on its Thykamine™ biopharmaceutical program, prioritizing a pivotal radiodermatitis prevention study, advancing preclinical MASH and fibrosis work, and evaluating strategic options for its Altius distribution business.
Devonian (OTCQB: DVHGF) reported Feb 19, 2026 preclinical human liver-on-a-chip results showing dose-dependent anti-fibrotic and anti-inflammatory activity for Thykamine™. In a 14-day PhysioMimix® MASH model, Thykamine reduced fibrosis biomarkers, Type I collagen deposition and lowered IL-6/IL-8, with strongest effects at 0.1–0.2 mg/mL.
LDH remained low (no drug-induced liver injury signal). Company plans additional preclinical studies to further characterize disease-modifying potential in MASH and other fibrotic diseases.
Devonian (OTCQB: DVHGF) announced that a proprietary Thykamine™ fingerprint has been filed in two patent applications and will be used in all future Thykamine filings. The fingerprint defines eight chemical components in precise ratios using HPLC‑MS, with NMR confirmation showing ≥98% batch‑to‑batch confidence.
Biological potency assays in a U‑937 human cell model demonstrated equivalent activity across batches, including consistent inhibition of inflammatory cytokines RANTES and MIP‑1β. The fingerprint, NMR, and potency assays are being integrated into Thykamine's CMC framework to support pharmaceutical development and regulatory preparedness.
Devonian (OTCQB: DVHGF) reported additional preclinical molecular data from its STAM mouse MASH study showing dose-dependent anti-MASH, anti-inflammatory and anti-fibrotic gene effects for Thykamine.
Oral dosing at 0.5, 5.0 and 50.0 mg/kg once daily for three weeks down‑regulated 29 fibrosis/inflammation genes, with several genes reduced by approximately 80–90% versus placebo and regional liver‑lobe differences observed.
Devonian Health (OTCQB: DVHGF) reported positive preclinical results for Thykamine in a bleomycin-induced pulmonary fibrosis mouse model on Feb 10, 2026. Thykamine, given orally at doses including 0.5 mg/kg, produced statistically significant reductions in lung wet weight, fibrosis (Ashcroft) and inflammation versus bleomycin controls.
Gene expression changes included downregulation of Fn1, Col1a1, Col3a1, Col6a1/3, Birc5, Ccl2, Cxcl2 and increased Mmp9 with reduced Mmp13, suggesting controlled matrix remodeling and antifibrotic activity. Pirfenidone at 220 mg/kg did not reach significance on physiological endpoints.
Devonian Health Group (OTCQB: DVHGF) appointed Dennis Turpin as Chief Financial Officer effective February 2, 2026; he will remain on the board and previously chaired the audit committee. The company granted Mr. Turpin 25,000 options vesting immediately at an $11.50 exercise price for 10 years.
The company corrected prior option disclosures: a pre-consolidation exercise price was revised from $0.18 to $0.19, then adjusted to $11.40 post-consolidation after a 1-for-60 share consolidation on January 22, 2026; option counts were rounded down per the plan.
Devonian Health Group (OTCQB: DVHGF; TSXV: GSD) announced a 1-for-60 share consolidation, approved by shareholders with 99.79% support, as part of preparations for a potential U.S. listing. The consolidation is subject to final TSXV acceptance and is expected to take effect at market open on or around January 22, 2026. Post-consolidation the company expects approximately 2,765,725 common shares outstanding (from 165,943,512 today), with no fractional shares issued and rounding to the nearest whole share. The OTCQB symbol will temporarily append a "D" for 20 business days after effectiveness. New CUSIP 251834883 and ISIN CA2518348834 will apply.
Devonian Health Group (OTCQB: DVHGF) announced on December 19, 2025 that its Board approved grants of stock options totaling 3,434,006 options. The grants consist of 2,948,056 options to directors and a consultant (including 2,798,056 to directors), 385,950 to employees as performance/retainer awards, and 100,000 to an R&D consultant.
The options are exercisable at $0.18 per share, expire 10 years from the grant date, and vest 25% on grant then 25% per year for three years.
Devonian Health Group (OTCQB: DVHGF) announced on December 4, 2025 the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." Researchers compared Thykamine™ with six widely prescribed anti-inflammatory drugs in an in vitro immune-activated cell model and reported that Thykamine™ inhibited MCP-1, MIP-1α and MIP-1β with greater potency than all comparators and suppressed RANTES comparable or superior to most agents tested. Effects occurred at lower concentrations and with no detectable cytotoxicity, suggesting a favorable tolerability profile and potential for further therapeutic development targeting chronic inflammatory and fibrotic conditions.